Last reviewed · How we verify
CKDB-501A
CKDB-501A is a small molecule that targets the SGLT2 receptor.
CKDB-501A is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | CKDB-501A |
|---|---|
| Sponsor | CKD Bio Corporation |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, CKDB-501A reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This makes it a potential treatment for type 2 diabetes. The exact molecular mechanism is not fully understood, but it is believed to involve the inhibition of SGLT2-mediated glucose transport.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- Efficacy and Safety of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines in Phase 3 Trial (PHASE3)
- Safety and Efficacy of CKDB-501A in Subjects With Post-stroke Upper Limb Spasticity (PHASE1)
- Safety and Efficacy of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CKDB-501A CI brief — competitive landscape report
- CKDB-501A updates RSS · CI watch RSS
- CKD Bio Corporation portfolio CI